07 October 2025
07 October 2025
Venture financing for mRNA vaccines have steeply dropped in 2025, market analysis shows.
The ADC offered significant improvements to overall survival (OS) in immunotherapy-ineligible patients.
The agreement gives Chiesi exclusive rights for the development and commercialisation of ABO-101 to treat PH1.
The proceeds will be used to further the development of NP-MP1 candidate through IND-enabling trials.
Drug manufacturers who test and produce their generic medicines on US soil will now have access to priority review.
Trogenix’s platform uses an AAV packed with two payloads in a “Trojan horse” approach to cancer treatment.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
